Prestan Products v. Innosonian America: Medical Training Device Patent Dismissed With Prejudice
Prestan Products LLC brought a patent infringement action against Innosonian America LLC and its Korean parent Innosonian Inc. in the District of New Jersey, asserting US8465293B2 covering a medical training device. After 795 days of litigation, all claims and counterclaims were dismissed with prejudice by stipulation under Rule 41(a).
CPR Manikin Patent Battle Ends in Mutual With-Prejudice Dismissal
On 26 January 2023, Prestan Products LLC — a manufacturer and patent holder in the medical simulation and CPR training device sector — filed suit in the United States District Court for the District of New Jersey against Innosonian America LLC and its South Korean parent Innosonian Inc., alleging infringement of US8465293B2, a patent covering a medical training device. Prestan, represented by Saul Ewing LLP, contended that Innosonian’s CPR training products embodied the claimed invention, and Innosonian’s counsel at Holland & Knight LLP and Sherman Atlas Sylvester & Stamelman LLP mounted a defence that included counterclaims against Prestan.
The case closed on 31 March 2025 via a joint stipulation under Federal Rule of Civil Procedure 41(a), whereby all claims asserted by Prestan and all counterclaims asserted by Innosonian America and Innosonian Inc. were dismissed with prejudice. Dismissal with prejudice is a final adjudication on the merits: Prestan is permanently barred from re-filing the same infringement claims against either Innosonian entity based on the same patent and accused conduct. The mutual nature of the stipulation — covering counterclaims as well — suggests both sides agreed to a clean break, consistent with a confidential settlement.
At 795 days, the matter ran longer than many patent cases that resolve before claim construction, suggesting the parties may have engaged in meaningful discovery or claim construction briefing before reaching agreement. The absence of any public damages award, royalty rate, or injunction order is consistent with confidential resolution. What drove the ultimate settlement — whether claim construction risks, invalidity exposure on US8465293B2, or commercial considerations in the CPR training device market — remains outside the public record.
Filing to Dismissed with Prejudice in 795 days
795 days — above the median duration for resolved D.N.J. patent cases
Dismissed with prejudice: what the joint stipulation means for both parties
Rule 41(a) stipulated dismissal with prejudice explained
A Rule 41(a) stipulated dismissal with prejudice requires agreement from all parties and operates as a final judgment on the merits. No court finding on validity or infringement is made — but the plaintiff permanently waives the right to refile the same claims against the same defendants. Both sets of claims and counterclaims were extinguished simultaneously, leaving no live dispute between these parties on US8465293B2.
Final — no re-filing permittedPrestan permanently forfeits infringement claims against Innosonian
By agreeing to dismissal with prejudice, Prestan Products cannot reassert the same infringement theory under US8465293B2 against Innosonian America or Innosonian Inc. for the accused conduct. In practice, this typically signals either a confidential settlement providing commercial relief, or a strategic decision that the cost and risk of continued litigation outweighed likely recovery. The patent itself remains in force and enforceable against unrelated third parties.
Patent survives; this defendant releasedInnosonian entities obtain finality — but counterclaims also extinguished
Innosonian America and Innosonian Inc. secured dismissal of Prestan’s infringement claims with prejudice — a commercially valuable outcome that eliminates future litigation risk from Prestan on the same patent and accused products. However, Innosonian’s own counterclaims (which may have sought invalidity or unenforceability of US8465293B2) were also dismissed with prejudice, meaning Innosonian forfeited any opportunity to invalidate the patent through this proceeding.
Counterclaims also permanently closedUS8465293B2 survives unchallenged — sector risk remains
Because the case resolved without any court ruling on validity or claim scope, US8465293B2 emerges from this litigation with its presumption of validity fully intact. Other CPR training device and medical simulation manufacturers cannot rely on this proceeding to narrow or invalidate the patent’s claims. Competitors operating in the manikin and medical training device space should treat US8465293B2 as an active enforcement risk and conduct independent freedom-to-operate analysis.
Patent validity untested — FTO warrantedFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | Prestan Products, LLC | Company | Medical simulation device manufacturer — holder of US8465293B2Search in Eureka ↗ |
| Defendant | Innosonian America, LLC | Company | CPR training device distributor (US) and its South Korean parent manufacturerSearch in Eureka ↗ |
| Co-Defendant | Innosonian, Inc. | Company | Search in Eureka ↗ |
| Plaintiff counsel | Alexander Lee Callo | Attorney | Counsel for Prestan Products, LLCSearch in Eureka ↗ |
| Plaintiff counsel | William C. Baton | Attorney | Counsel for Prestan Products, LLCSearch in Eureka ↗ |
| Plaintiff law firm | Saul Ewing LLP | Law Firm | Representing Prestan Products, LLCSearch in Eureka ↗ |
| Defendant counsel | Charles A. Weiss | Attorney | Counsel for Innosonian America, LLCSearch in Eureka ↗ |
| Defendant counsel | Joshua S. Bratspies | Attorney | Counsel for Innosonian America, LLCSearch in Eureka ↗ |
| Defendant counsel | LAUREN WATSON | Attorney | Counsel for Innosonian America, LLCSearch in Eureka ↗ |
| Defendant law firm | HOLLAND & KNIGHT LLP | Law Firm | Representing Innosonian America, LLCSearch in Eureka ↗ |
| Defendant law firm | Sherman Atlas Sylvester & Stamelman LLP | Law Firm | Representing Innosonian America, LLCSearch in Eureka ↗ |
| Presiding judge | Judge N/A | Judge | New Jersey District CourtSearch in Eureka ↗ |
Official order — verbatim text
The stipulation expressly covers ‘all claims and counterclaims’ among all three named parties, drafted with deliberate symmetry to ensure complete finality. The with-prejudice qualifier on both sides’ claims confirms this is not a procedural housekeeping dismissal but a negotiated end-state. Notably, the verdict text does not reference any royalty, damages figure, or injunctive relief, which is consistent with a confidential settlement whose commercial terms are not publicly disclosed. The bilateral extinguishment of counterclaims is particularly significant: had Innosonian’s invalidity counterclaims succeeded, US8465293B2 could have been rendered unenforceable against all parties — that outcome is now foreclosed.
US8465293B2 — Medical Training Device (CPR Manikin Technology)
US8465293B2, filed under application number US12/782829, protects a medical training device — technology associated with CPR manikins and resuscitation simulation equipment used in first-aid and clinical training contexts. Prestan Products LLC, the assignee, is a recognised manufacturer in this niche, and the patent represents core IP in its product portfolio. The patent’s claims define the structural and functional parameters of the training device, making claim scope central to any infringement or design-around analysis.
In the CPR training device sector, patent protection on manikin design and feedback mechanisms carries significant commercial weight: training certification bodies and institutional purchasers favour a small number of compliant manufacturers, creating concentrated market dynamics. A patent of this type asserted against a direct competitor — particularly one with a Korean parent supplying units globally — signals that Prestan is actively defending market position through IP enforcement. The case’s resolution without invalidity determination leaves US8465293B2 as a meaningful barrier to entry for new market participants.
Should you run an FTO analysis against US8465293B2?
Any company developing, manufacturing, importing, or distributing CPR training manikins, resuscitation simulation devices, or adjacent medical training equipment in the United States should treat US8465293B2 as a priority FTO target. This case confirms Prestan is willing to litigate and that the patent has survived a two-year enforcement action without any adverse validity ruling. If your product falls within the medical simulation or first-responder training device category, an independent claim-by-claim FTO assessment is essential before US commercialisation.
PatSnap Eureka’s FTO Search Agent allows R&D and IP teams to map US8465293B2’s independent and dependent claims against product specifications, identify prior art that could support design-around strategies, and flag continuation applications that may extend the patent family’s coverage. With the patent’s validity untested in this litigation, Eureka’s prior art discovery tools provide the fastest path to understanding whether a valid design-around or IPR challenge petition is commercially viable for your product roadmap.
Run a freedom-to-operate analysis on US8465293B2 to assess your product’s exposure
Run FTO in Eureka →Similar Patent Cases in Medical Training Device & D.N.J. IP Litigation
Explore related patent infringement actions involving medical simulation and CPR training device technology filed in the District of New Jersey and comparable venues.
What this case signals for the medical training device IP landscape
A with-prejudice mutual dismissal after 795 days in D.N.J. carries specific signals for CPR device manufacturers and their IP teams.
US8465293B2 was never invalidated — treat it as live enforcement risk
No claim construction order, IPR petition, or invalidity ruling was issued. The patent exits this case with its claims intact and its presumption of validity undiminished. Any competitor whose products involve CPR manikin or medical simulation technology should conduct a fresh FTO analysis against the current claim set before launching or expanding product lines.
Mutual with-prejudice dismissal typically signals confidential settlement
When both claims and counterclaims are dismissed with prejudice simultaneously under Rule 41(a), it strongly suggests the parties reached a private commercial resolution. In competitive markets like CPR training devices, such agreements may include licensing terms, design-around covenants, or market-sharing arrangements — none of which appear in the public record, but which can affect competitive dynamics.
Prestan v Innosonian — key questions answered
The case was dismissed with prejudice by joint stipulation under Rule 41(a) on 31 March 2025. All claims by Prestan Products and all counterclaims by Innosonian America and Innosonian Inc. were permanently extinguished. No court ruling on patent validity or infringement was issued, and no public damages or royalty award appears on the docket.
Prestan Products asserted US8465293B2, filed under application number US12/782829, which covers a medical training device — technology associated with CPR manikins and resuscitation simulation equipment. The patent remains in force following dismissal, as its validity was never adjudicated in this proceeding.
No. A with-prejudice dismissal by stipulation binds only the named parties — Prestan Products, Innosonian America, and Innosonian Inc. US8465293B2 remains fully enforceable against any other party. The dismissal does not constitute a finding of invalidity or non-infringement that third parties could invoke as prior art or collateral estoppel.
Innosonian had asserted counterclaims — likely including invalidity or unenforceability of US8465293B2. Their dismissal with prejudice means Innosonian cannot re-litigate those specific theories in any subsequent federal court action. However, Innosonian or any third party could still file an inter partes review (IPR) petition at the USPTO challenging the patent’s validity, as that administrative avenue is separate from district court proceedings.
The 795-day duration is consistent with cases that proceed through substantial discovery and potentially claim construction briefing before the parties reach commercial resolution. Patent cases in D.N.J. frequently involve extensive fact discovery on technical and commercial issues before settlement leverage becomes clear. The specific litigation milestones that influenced the parties’ decision to settle are not disclosed in the public record.
PatSnap Eureka searches patents and litigation data to answer instantly.